Protalix BioTherapeutics's top three insider shareholders as of April 17, 2026 are Dror Bashan (President And Ceo, 2.34Mn shares), Eyal Rubin (Sr. Vp And Cfo, 660.91K shares), Aharon Schwartz (Director, 303.00K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Dror Bashan | President And Ceo | 0 | 2,344,418 | 04 Sep, 2025 |
| Eyal Rubin | Sr. Vp And Cfo | 0 | 660,909 | 05 Nov, 2024 |
| Aharon Schwartz | - | 303,000 | 0 | 12 Aug, 2025 |
| Yaron Naos | Sr. Vp, Operations | 0 | 225,817 | 04 Sep, 2025 |
| Dror Bashan | President And Ceo | 188,516 | 0 | 23 Dec, 2025 |
| Yael Hayon | Vp, Research Development | 0 | 35,115 | 17 Aug, 2023 |
| Christian Elze | - | 0 | 7,500 | 04 Sep, 2025 |
| Aharon Schwartz | - | 0 | 7,500 | 04 Sep, 2025 |
| Amos Bar-Shalev | - | 0 | 7,500 | 04 Sep, 2025 |
| Pol F Boudes | - | 0 | 7,500 | 04 Sep, 2025 |
| Zvi Shmuel Ben | - | 0 | 7,500 | 04 Sep, 2025 |
| Gwen A Melincoff | - | 0 | 7,500 | 04 Sep, 2025 |
| Eliot Forster | - | 0 | 7,500 | 04 Sep, 2025 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 19 Dec, 2025 | Dror Bashan | Common Stock | A | 56,000 | $1.81 | 188,516 | D | P |
| 18 Nov, 2025 | Amos Bar-Shalev | Common Stock | D | 168 | $1.87 | 0 | D | S |
| 03 Sep, 2025 | Eliot Forster | Common Stock | A | 7,500 | - | 7,500 | I | A |
| 03 Sep, 2025 | Gwen A Melincoff | Common Stock | A | 7,500 | - | 7,500 | I | A |
| 03 Sep, 2025 | Dror Bashan | Common Stock | A | 195,000 | - | 2,344,418 | I | A |
| 03 Sep, 2025 | Yaron Naos | Common Stock | A | 25,000 | - | 225,817 | I | A |
| 03 Sep, 2025 | Zvi Shmuel Ben | Common Stock | A | 7,500 | - | 7,500 | I | A |
| 03 Sep, 2025 | Pol F Boudes | Common Stock | A | 7,500 | - | 7,500 | I | A |
| 03 Sep, 2025 | Christian Elze | Common Stock | A | 7,500 | - | 7,500 | I | A |
| 03 Sep, 2025 | Aharon Schwartz | Common Stock | A | 7,500 | - | 7,500 | I | A |
| 03 Sep, 2025 | Amos Bar-Shalev | Common Stock | A | 7,500 | - | 7,500 | I | A |
| 03 Sep, 2025 | Christian Elze | Stock Options (Right to Buy) | A | 15,000 | $0.00 | 15,000 | D | A |
| 03 Sep, 2025 | Gwen A Melincoff | Stock Options (Right to Buy) | A | 15,000 | $0.00 | 15,000 | D | A |
| 03 Sep, 2025 | Zvi Shmuel Ben | Stock Options (Right to Buy) | A | 15,000 | $0.00 | 15,000 | D | A |
| 03 Sep, 2025 | Eliot Forster | Stock Options (Right to Buy) | A | 15,000 | $0.00 | 15,000 | D | A |
| 03 Sep, 2025 | Amos Bar-Shalev | Stock Options (Right to Buy) | A | 15,000 | $0.00 | 15,000 | D | A |
| 03 Sep, 2025 | Aharon Schwartz | Stock Options (Right to Buy) | A | 15,000 | $0.00 | 15,000 | D | A |
| 03 Sep, 2025 | Pol F Boudes | Stock Options (Right to Buy) | A | 15,000 | $0.00 | 15,000 | D | A |
| 03 Sep, 2025 | Yaron Naos | Stock Option (Right to Buy) | A | 50,000 | $0.00 | 50,000 | D | A |
| 03 Sep, 2025 | Dror Bashan | Stock Option (Right to Buy) | A | 340,000 | $0.00 | 340,000 | D | A |